Literature DB >> 32606565

Coronaviruses' sugar shields as vaccine candidates.

Denong Wang1.   

Abstract

A successful global healthcare response relies on versatile vaccines and production of broadly virus-neutralizing antibodies by the immune system to protect us from emerging infectious diseases. The present 2019 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic highlights the urgent need for development of anti-viral biodefense. Due to the genetic and proteomic diversities of viral pathogens, establishing versatile anti-viral vaccines or therapeutic agents is highly challenging. Carbohydrate antigens represent an important class of immunological targets for vaccine development and immunotherapy against microbial infections. In this mini review, some concepts and strategies for exploring the potential of immunogenic sugar moieties as CoV vaccine candidates are presented.

Entities:  

Keywords:  COVID-19; N-glycans; SARS; SARS-CoV-2; coronavirus; glyco-conjugate; lectin; oligomannoses; spike glycoprotein; vaccines; virus-neutralizing antibody

Year:  2020        PMID: 32606565      PMCID: PMC7326345     

Source DB:  PubMed          Journal:  Curr Trends Immunol        ISSN: 0972-4567


  66 in total

1.  Safety and immunologic response to Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in 1- to 6-month-old infants.

Authors:  D V Madore; C L Johnson; D C Phipps; L A Popejoy; R Eby; D H Smith
Journal:  Pediatrics       Date:  1990-03       Impact factor: 7.124

2.  Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?

Authors:  Francesco Negro
Journal:  Swiss Med Wkly       Date:  2020-04-16       Impact factor: 2.193

3.  Haemophilus influenzae type B polysaccharide-protein conjugates: model for a new generation of capsular polysaccharide vaccines.

Authors:  R Schneerson; J B Robbins; O Barrera; A Sutton; W B Habig; M C Hardegree; J Chaimovich
Journal:  Prog Clin Biol Res       Date:  1980

4.  Human coronavirus 229E can use CD209L (L-SIGN) to enter cells.

Authors:  Scott A Jeffers; Erin M Hemmila; Kathryn V Holmes
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

5.  Carbohydrate antigen microarrays.

Authors:  Denong Wang
Journal:  Methods Mol Biol       Date:  2012

6.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

Authors:  Daniel Wrapp; Nianshuang Wang; Kizzmekia S Corbett; Jory A Goldsmith; Ching-Lin Hsieh; Olubukola Abiona; Barney S Graham; Jason S McLellan
Journal:  Science       Date:  2020-02-19       Impact factor: 47.728

7.  Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV.

Authors:  Ming Zheng; Lun Song
Journal:  Cell Mol Immunol       Date:  2020-03-04       Impact factor: 11.530

8.  Oxidative release of natural glycans for functional glycomics.

Authors:  Xuezheng Song; Hong Ju; Yi Lasanajak; Matthew R Kudelka; David F Smith; Richard D Cummings
Journal:  Nat Methods       Date:  2016-05-02       Impact factor: 28.547

9.  Timely development of vaccines against SARS-CoV-2.

Authors:  Shan Lu
Journal:  Emerg Microbes Infect       Date:  2020-03-08       Impact factor: 7.163

10.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

View more
  4 in total

1.  Glycosylation and S-palmitoylation regulate SARS-CoV-2 spike protein intracellular trafficking.

Authors:  Chih-Feng Tien; Wan-Ting Tsai; Chun Hwa Chen; Hui-Ju Chou; Mingzi M Zhang; Jhe-Jhih Lin; En-Ju Lin; Shih-Syong Dai; Yueh-Hsin Ping; Chia-Yi Yu; Yi-Ping Kuo; Wei-Hsiang Tsai; Hsin-Wei Chen; Guann-Yi Yu
Journal:  iScience       Date:  2022-07-03

2.  Customized peptidoglycan surfaces to investigate innate immune recognition via surface plasmon resonance.

Authors:  Ha T Le; Elizabeth A D'Ambrosio; Siavash Mashayekh; Catherine Leimkuhler Grimes
Journal:  Methods Enzymol       Date:  2022-01-13       Impact factor: 1.682

Review 3.  SARS-CoV-2 replicating in nonprimate mammalian cells probably have critical advantages for COVID-19 vaccines due to anti-Gal antibodies: A minireview and proposals.

Authors:  Ji-Ming Chen
Journal:  J Med Virol       Date:  2020-08-02       Impact factor: 20.693

Review 4.  The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens.

Authors:  Liangwei Duan; Qianqian Zheng; Hongxia Zhang; Yuna Niu; Yunwei Lou; Hui Wang
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.